Rxrx stock forecast.

Next reporting date: February 14, 2024: EPS forecast (this quarter) $0.95: Annual revenue (last year) $2.2B: Annual profit (last year) $42.8M: Net profit marginRecursion Pharmaceuticals Inc. 7.06. Delayed Data. As of Nov 17. +0.39 / +5.85%. Today’s Change. 4.54. Today ||| 52-Week Range. 16.75.RXRX : RECURSION PHARMACEUTICALS-A stock forecast by Wall Street Analysts. The average RECURSION PHARMACEUTICALS-A stock forecast from last 6 month is $16.9, and this show a 3.7% increase in average from the prior price target of the each prediction.As of Monday, July 24, Recursion Pharmaceuticals Inc’s RXRX share price has dipped by 7.69%, which has investors questioning if this is right time to buy. Premium ... Whether you decide it’s a good time to buy or sell Recursion Pharmaceuticals Inc’s stock based on its stock price forecast is ultimately up to you.Nov 24, 2023 · The Recursion Pharmaceuticals, Inc. stock price gained 1.18% on the last trading day (Friday, 24th Nov 2023), rising from $6.78 to $6.86. During the last trading day the stock fluctuated 5.06% from a day low at $6.71 to a day high of $7.05. The price has risen in 7 of the last 10 days and is up by 31.17% over the past 2 weeks.

View the latest Recursion Pharmaceuticals Inc. (RXRX) stock price, news, historical charts, analyst ratings and financial information from WSJ.12 июл. 2023 г. ... Recursion stock is up after Nvidia investment and collaboration. Time to buy RXRX Stock? or time to buy Nvidia Stock Price? A portion of ...

Recursion Pharmaceuticals, Inc. (RXRX) : Free Stock Analysis Report. Omega Therapeutics, Inc. (OMGA) : Free Stock Analysis Report ... according to the …Recursion Pharmaceuticals (RXRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.The company raised guidance for annual organic revenue growth from an earlier forecast of between 5% and 7% to between 6% and 8%. It also raised annual adjusted EPS to be between $3.70 and $3.85 ...Dec 1, 2023 · The Xerox Corporation stock price gained 1.29% on the last trading day (Friday, 1st Dec 2023), rising from $13.99 to $14.17. During the last trading day the stock fluctuated 4.56% from a day low at $13.60 to a day high of $14.22. The price has risen in 6 of the last 10 days and is up by 4.34% over the past 2 weeks. Stock Price Forecast. The 7 analysts offering 12-month price forecasts for Recursion Pharmaceuticals Inc have a median target of 14.00, with a high estimate of 35.00 and a low estimate of 9.00 ...

Weather forecasts are essential tools for planning our daily activities, especially when it comes to the next 10 days. Understanding a weather 10 day forecast can help us make informed decisions about outdoor events, travel plans, or even w...

Wall Street is abuzz with the news of Nvidia’s $50 million investment in Recursion Pharmaceuticals (NASDAQ:RXRX). The biotech company’s stock surged over 120% following the announcement ...

When it comes to complex biotech stocks like Recursion Pharmaceuticals (RXRX 7.88%), skilled investors are likely to have an outsized advantage in understanding how the future will play out ...5 analysts have issued 12 month price objectives for Amneal Pharmaceuticals' stock. Their AMRX share price targets range from $3.00 to $7.00. On average, they anticipate the company's share price to reach $4.80 in the next year. This suggests a possible upside of 9.3% from the stock's current price.Explore RXRX - Recursion Pharmaceuticals Inc Stock Price Forecast: Accurate short-term and long-term price predictions up to 2050. ... Stock Calculator; Dow: 35,088. ... Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock quote, history, news and other vital information to help you with your stock trading and investing.Discover historical prices for RXRX stock on Yahoo Finance. View daily, weekly or monthly format back to when Recursion Pharmaceuticals, Inc. stock was issued.A high-level overview of Recursion Pharmaceuticals, Inc. (RXRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

What is Recursion Pharmaceuticals, Inc. (RXRX) stock EPS forecast? Recursion Pharmaceuticals, Inc. missed analysts’ expectations during the last earnings period by 13.16% . Recursion Pharmaceuticals, Inc. reported earnings of -$ 0.43 per share on Nov 9, 2023, while the forecasted EPS was -$ 0.38.Complete Recursion Pharmaceuticals Inc. stock information by Barron's. View real-time RXRX stock price and news, along with industry-best analysis.Analysts have provided the following ratings for Recursion Pharmaceuticals (NASDAQ:RXRX) within the last quarter: These 7 analysts have an average price target of $18.14 versus the current price ...Currently, Wall Street analysts expect the stock to reach $16.00 within the next 12 months. Recursion Pharmaceuticals Inc [NASDAQ: RXRX] shares were valued at $6.11 at the most recent close of the market. An investor can expect a potential return of 161.87% based on the average RXRX price forecast.60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share.As of Monday, August 07, Recursion Pharmaceuticals Inc’s RXRX share price has dipped by 11.05%, which has investors questioning if this is right time to buy. Premium ... Whether you decide it’s a good time to buy or sell Recursion Pharmaceuticals Inc’s stock based on its stock price forecast is ultimately up to you.

Meta Platforms ( META ): META’s revenues climbed 23% to $34.15 billion in its most recent quarter. Teradyne ( TER ): Resilient Teradyne outshone in the third quarter with an 80-cent Non-GAAP EPS ...

See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. RXRX's current price target is …On the bottom line, Recursion's net loss per share of $0.38 remained flat compared to the prior-year quarter. The company ended the period with $405.9 million in cash and equivalents, which does ...Stock Price Forecast. According to 6 stock analysts, the average 12-month stock price forecast for RXRX stock stock is $15.33, which predicts an …Before the stock market opened, RXRX stock had catapulted more than 130%. Nvidia stock rose 3.5% to 439.02. Recursion has a searchable data set spanning biology and chemistry. The company says its ...Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.Recursion Pharmaceuticals (RXRX 7.88%) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug ...

Zillow is worth $8.3 billion right now, so if it reaches its 2025 sales estimate and continues to grow thereafter, it should breeze past a $10 billion valuation by 2030. 2. Duolingo: Potential ...

We’ve all flipped between different weather apps, wondering why each is giving a slightly different report. Before we look at AccuWeather, it’s important to understand the basics of weather forecasting. In the past, weather predictions were...

Recursion Pharma may be a biotech stock, but it scored a $50 million investment from Nvidia to fund its AI technology in mid-July - making NVDA a significant stakeholder in RXRX. The partnership ...Taken together with their deep financial resources, Eli Lilly is one of the best positioned companies to take advantage of the AI-biotech trend. Because Eli Lilly’s future is built off a very ...Nov 27, 2023 · What are analysts forecasts for Recursion Pharmaceuticals, stock? The 21 analysts offering price forecasts for Recursion Pharmaceuticals, have a median target of 14.62, with a high estimate of 33. ... Jul 13, 2023 · The US$14.13 analyst price target for RXRX is 3.5% ... we will estimate the stock's intrinsic value by taking the forecast future cash flows of the company and discounting them back to today's ... According to data from CNN Money, the company had 7 analysts offering 12-month price forecasts. The median target price was $14.00, with a high estimate of $35.00 and a low estimate of $9.00. The consensus among the 7 polled investment analysts was to hold the stock of Recursion Pharmaceuticals Inc. This rating had remained steady since ...Analyst projections state that RXRX is forecast to be at a low of $9.00 and a high of $35.00. In order for the stock price to hit the forecast high, the stock would need to plunge -435.99% from its current level, while the stock would need to crash -37.83% from its current level to reach the projected low.Dec 1, 2023 · View Recursion Pharmaceuticals, Inc RXRX investment & stock information. Get the latest Recursion Pharmaceuticals, Inc RXRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Next reporting date: February 14, 2024: EPS forecast (this quarter) $0.95: Annual revenue (last year) $2.2B: Annual profit (last year) $42.8M: Net profit marginRecursion Pharmaceuticals (RXRX 7.88%) and Exact Sciences (EXAS 4.73%), two of Wood's larger biopharma holdings across her family of tech-oriented ETFs, are prime examples of the pros and cons ...

Based on short-term price targets offered by seven analysts, the average price target for Recursion Pharmaceuticals comes to $15.29. The forecasts range from a …Jul 13, 2023 · Recursion Pharmaceuticals, Inc. (RXRX) : Free Stock Analysis Report. Omega Therapeutics, Inc. (OMGA) : Free Stock Analysis Report ... according to the forecast. 7h ago. Zacks. 2 Stocks to Buy from ... In particular, both Ginkgo Bioworks (NYSE: DNA) and Recursion Pharmaceuticals (NASDAQ: RXRX) are already implementing AI, and in the long term, it could be a crucial factor in their success.Recursion Pharmaceuticals Stock Prediction. BSX. 63Instagram:https://instagram. oark stock dividendlearn day trading onlinedental discount plan vs insuranceus housing shortage (See RXRX stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.NVDA stock has risen 3% in July, outperforming the Nasdaq Index, and has surged 200% this year, ... RXRX). The biotech company’s stock surged over 120% following the announcement, ... hnacx stockmreits Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you. tradovate inactivity fee Market Activity. Funds + ETFs. News + Insights. P/E & PEG Ratios. Nasdaq provides the ownership stake information in a company, including the number of shares held by those institutions in a firm ...(See RXRX stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy , a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst.Dec 1, 2023 · RXRX Stock Overview. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.